Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This limits cell proliferation, especially in rapidly dividing tissues such as immune cells and malignant cells, and also increases extracellular adenosine, which has anti‑inflammatory properties.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosage regimens vary widely, and the prescriber determines the appropriate amount and frequency.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and death. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate is a first‑line antimetabolite with a well‑established efficacy and safety profile for both autoimmune diseases and certain cancers. Compared with newer agents like leflunomide or biologics, methotrexate is generally less expensive but requires regular monitoring for toxicity. Its broad therapeutic range makes it a versatile option.

Metoject should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperature fluctuations to maintain stability and potency.

Metoject is supplied as a sterile injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. The route, site and frequency are determined by the treating physician based on the indication and patient-specific factors.

The most serious risks include bone marrow suppression leading to severe anemia or infection, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be monitored regularly for these complications.

Metoject is contraindicated in pregnant women, nursing mothers, and patients with severe renal or hepatic impairment. Individuals with known hypersensitivity to methotrexate or any component of the formulation should also avoid its use.